Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting.

ABSTRACT:

Background

In the United States, Black men have a higher incidence of prostate cancer (PC)-related mortality than men of other races. Several real-world studies in advanced PC suggest, however, that Black men respond better to novel hormonal therapies than White men. Data on treatment responses to enzalutamide by race are limited. We assessed real-world prostate-specific antigen (PSA) response and clinical progression-free survival (cPFS) of Black vs. White men with chemotherapy-naïve PC treated with enzalutamide.

Methods

This retrospective cohort study included patients with PC who initiated enzalutamide treatment from 2014 to 2018 in the IntrinsiQ Specialty Solutions™ database, a collection of electronic medical records from community urology practices. Index date was the

SUBMITTER: Freedland SJ 

PROVIDER: S-EPMC10449620 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature